Loading company…
Model Medicines uses AI and machine learning to support drug discovery.
Founded in 2019 in the United States, Model Medicines develops AI and machine learning tools for drug discovery. Its GALILEO™ platform has identified 192 compounds and advanced 67 assets across 12 therapeutic targets, including infectious diseases and oncology. The company works with academic institutions and corporate laboratories. In September 2024, it raised USD 14.75 mn in Seed funding.
2 rounds recorded · latest Private placement (Form D), Oct 2026
Sign in to see 2 rounds.
Sign inSign in to see 3 investors.
Sign inModel Medicines, Inc. has no recorded acquisitions.
Add an acquisitionStill private — no exit on record.
Record an exitNo diversity signals recorded yet for Model Medicines, Inc..
Add diversity data